No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Minnetronix Medical Announces Recapitalization with Altaris Capital Partners

Editor: What To Know

  • Headquartered in Minnesota, Minnetronix Medical focuses on product development and manufacturing across the full product life cycle with specialized expertise in key technology segments, including RF energy, fluid and gas management, optical systems, and stimulation and wearable devices.
  • The company also recently launched its whole product solutions, offering ready-made products and solutions for customers to add to their portfolios, as evidenced by the FDA- approved MindsEyeTM Expandable Port for critical access in interventional neurosurgical procedures.
  • “We are excited to expand our partnership with Minnetronix and build on the company's rich heritage of accelerating medical device innovation for its customers,” said Jim O'Brien, managing director at Altaris.

February 3, 2021

Minnetronix Medical CEO Jeremy Maniak said, “Throughout our relationship with Altaris, we have achieved many milestones as a company. Now, with our expanded partnership, we are excited to accelerate our strategy and move into the next stage of growth at Minnetronix.”

Headquartered in Minnesota, Minnetronix Medical focuses on product development and manufacturing across the full product life cycle with specialized expertise in key technology segments, including RF energy, fluid and gas management, optical systems, and stimulation and wearable devices. The company also recently launched its whole product solutions, offering ready-made products and solutions for customers to add to their portfolios, as evidenced by the FDA- approved MindsEyeTM Expandable Port for critical access in interventional neurosurgical procedures.

Minnetronix Medical holistic, solutions-driven approach is unique in the industry. The company maximizes clinical performance, improves product quality, and lowers costs for its customers by eliminating waste through integrated development, manufacturing and supply chain processes.

“We are excited to expand our partnership with Minnetronix and build on the company’s rich heritage of accelerating medical device innovation for its customers,” said Jim O’Brien, managing director at Altaris. “We look forward to working with the Minnetronix team to support the company’s next phase of growth.”

Fox Rothschild LLP acted as legal counsel for Minnetronix Medical. Schiff Hardin LLP acted as legal counsel for Altaris.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy